We supply Favipiravir API

We offer Favipiravir API, a potent antiviral drug used in the treatment of influenza contagions, including COVID- 19. Our product possesses high chastity and stability, enabling its wide use in the pharmaceutical assiduity to produce colorful phrasings of the medicine. Our product is manufactured under strict quality control measures, icing our guests admit a dependable and effective product. With our commitment to furnishing exceptional client service, we offer competitive pricing and fast and effective shipping worldwide. Choose our Favipiravir powder to support your exploration and development requirements in combating viral infections.

What's Favipiravir?

Favipiravir is an antiviral medicine that has generated significant interest due to its eventuality as a treatment for multitudinous viral infections. This drug is specifically designed to target RNA contagions and has been shown to inhibit the replication of contagions similar as influenza, Ebola, and SARS- CoV- 2( the contagion that causes COVID- 19).
it workshop by snooping with the contagion's capability to replicate its inheritable material. This, in turn, can help help the contagion from spreading throughout the body and causing more severe symptoms. Because of this medium of action, it is particularly effective when given early in the course of infection.
Studies on the effectiveness  as a treatment for certain viral infections have yielded promising results. For illustration, a study of cases with mild to moderate COVID- 19 set up that those entering it had a shorter time to clinical recovery compared to those entering a placebo. also, a study of cases with influenza set up that it was more effective at reducing viral cargo than another antiviral drug.
Despite promising results, it isn't without side goods. Common side goods may include gastrointestinal symptoms similar as nausea, puking, and diarrhea, as well as elevated uric acid situations in the blood. This drug isn't recommended for use during gestation or breastfeeding, and caution should be exercised when defining to cases with a history of gout or order complaint.
Overall, it represents a potentially precious treatment option for certain viral infections. still, further exploration is demanded before it can be extensively used as a standard treatment for these conditions.

Basic Information

Product Name: Favipiravir

CAS NO.: 259793-96-9

MF:C5H4FN3O2

MW:157.1

EINECS:1533716-785-6

MDL No.:MFCD12032148

Structural formula:

Purity: 99%+

Origin: China

Application: antiviral

Delivery Time: in stock

Technical Specification

Package: 1kg; 25kg

Storage conditions: keep tightly closed, store in a cool dry place.

Mechanism of action

Favipiravir API is a nucleoside antiviral drug, and its mechanism of action has not been fully elucidated. Its target is the viral RNA dependent RNA polymerase. After oral absorption, the drug is converted into a biologically active nucleoside triphosphate, which has a structure similar to purine Chemicalbook and can compete with purine for viral RNA polymerase; The nucleoside triphosphate can also be inserted into the viral RNA chain, inducing lethal mutations in the virus. Therefore, from a mechanistic perspective, it has potential antiviral effects against various RNA viruses.

What is the application？

Favipiravir powder can be used for antiviral treatment of influenza A and B. Research has shown that in addition to influenza viruses, the drug also exhibits good antiviral activity against various RNA viruses, such as Ebola virus, sandvirus, Bunyavirus, rabies virus, etc.

Related research

Favipiravir, chemical name is 6-fluoro-3-hydroxypyrazin-2-formamide, is a new broad-spectrum antiviral drug targeting RNA dependent RNA polymerase (RdRp) developed by Toyama Chemical Pharmaceutical Company of Japan. In March 2014, Chemicalbook was approved for listing in Japan for the treatment of new and recurrent influenza. During the outbreak of novel coronavirus, the Phase I clinical research results of the drug published in March 2020 showed that the drug could alleviate the progress of novel coronavirus pneumonia by accelerating virus clearance.

In vitro research

Favipiravir exhibits anti influenza virus activity, with an IC50 range of 0.013-0.48 for influenza A, influenza B, and influenza C viruses, respectively μ G/ml, 0.039-0.089 μ G/ml, and 0.030-0.057 μ G/ml. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, Hela cells, and Hep-2 cells), up to 1000 μ FavipiraviChemicalbookr at a concentration of g/ml did not exhibit toxicity. it induces lethal mutations in MDCK cells inoculated with seasonal influenza A (H1N1) virus.

In vivo research

In mice infected with influenza virus, Favipiravir (200mg/kg/day, p.o.) protects them from infection and death caused by influenza virus. In mice artificially infected with Ebola virus,it effectively blocked virus production and achieved antiviral effects of 95% and 99.6% on the first 2 days and 6 days of treatment, respectively.

Payment Term

Why Choose Xi'an Yihui?

Customer feedback

Xi'an Yihui certificates

Xi'an Yihui Factory & Warehouse

Contact us

as a professional Favipiravir APImanufacturer, we have advanced technology, scale advantage, the best quality, rich production experience, and excellent services. These advantages will make it stand out in the market competition and win more customer trust and support. if you need Favipiravir powder, pls feel free to contact us any time. we will reply you asap.

our contact information:

E-mail: sales@yihuipharm.com
Tel: 0086-29-89695240
WeChat or WhatsApp: 0086-17792415937